Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | PLK1 | P53350 | 1/20 | 0.66 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28071106 | 0.86 | PLK1 (0.61) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL28071020 | 0.84 | TAS1R3 (0.59) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL1644905 | 0.83 | MEN1 (0.61) | RAB9ANPC1HDAC1HDAC2ALDH1A1 | |
| SCHEMBL13491356 | 0.83 | ALOX15 (0.57) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL31419202 | 0.83 | PLK1 (0.72) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL3492806 | 0.83 | PLK1 (0.72) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL28071104 | 0.82 | ALOX15 (0.71) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL1680321 | 0.81 | PLK1 (0.66) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL16621111 | 0.81 | PLK1 (0.66) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL13491384 | 0.81 | ALOX15 (0.55) | ALOX15HTTPLK1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2018383-B1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PROD INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-2265614-A1 | IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-7732604-B2 | Triazolopyrazine derivatives | PFIZER INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| WO-2009106577-A1 | IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION | 2009-02-12 | — | — | US | disclosed |
| EP-2018383-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Pfizer Products Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| US-7468446-B2 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2007132308-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2007-11-15 | — | — | US | disclosed |
| EP-1794139-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006028963-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052596-A1 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | ALOX15 3630/4885HTT 3764/4885PLK1 1104/4885 |
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | JAK2, ABL1, CCND2 | ALOX15 4343/4885HTT 1869/4885PLK1 381/4885 |
| US-20060052596-A1 | Substituted heterocyclic compounds and uses thereof | NQO1, LTC4S, VHL | ALOX15 171/4885HTT 235/4885PLK1 4432/4885 |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | JAK2, ABL1, CCND2 | ALOX15 4343/4885HTT 1869/4885PLK1 381/4885 |
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | NQO1, LTC4S, VHL | ALOX15 171/4885HTT 235/4885PLK1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.